Small-Molecules Targeting Sirtuin 1: A Patent Review (2012-2015)

Alessandra Graziadio, Alessandra Locatelli*, Rita Morigi and Mirella Rambaldi

The Department of Pharmacy and Biotechnology FaBiT, University of Bologna, Via Belmeloro, 6, Bologna, Italy

Abstract

Sirtuins are a family of enzymes, which govern genome regulation, stress response, metabolic homeostasis and lifespan. Among all the discovered human isoforms (SIRT1-7), SIRT1 emerged as a promising molecular target for the treatment of several diseases. The SIRT1 activators have shown beneficial effects in diabetes, obesity, disorders related to aging, cardiovascular and neurodegenerative diseases. On the other hand, SIRT1 inhibition could be applied in anticancer therapy. This review is focused on patents regarding small molecules targeting SIRT1 registered from 2012 to 2015. The chemical formula, the activation and/or inhibition activity and the application of the most active compounds are considered.

Keywords: SIRTs; Modulation; SIRT1-inhibitors; Anticancer; SIRT1-activators; Identification assays; Metabolic disorders; Resveratrol

Introduction

Sirtuins are a family of enzymes, widely distributed in organisms ranging from archaea to humans, involved in various biological processes, such as transcription, cell survival, genome stability and instability, DNA damage and repair, and longevity [1]. The silent information regulator 2 (Sir2) was the first sirtuin identified in yeast, other examples are the bacterial CobB sirtuins (isoforms Sir2Tm and Rv1151c), the archaeal sirtuins (Sir2A1f and Sir2A2), while SIRTs1-7 are present in mammals [2].

Sirtuins share a highly conserved catalytic core but differ in N and C-terminal extensions. The catalytic core consists of two domains: a larger Rossmann-fold domain typical for NAD+ binding proteins and a smaller, more variable zinc-binding domain. The zinc ion is coordinated by four invariant cysteines and appears essential for the stability of the protein. The acetylated substrate and the NAD+ co-substrate bind in a cleft between the two domains thereby inducing closure of the active site and stabilization of a so-called cofactor binding loop. In a productive conformation, the nicotinamide moiety of NAD+ is buried in the highly conserved C-pocket [3].

These enzymes catalyze the deacetylation of specific Nε-acetyl-lysines (AcK) on several protein substrates, such as histones, transcription factors and enzymes, utilizing nicotinamide adenine dinucleotide (NAD+) as co-substrate. The enzymatic reaction involves the acetyl group transfer from AcK to ADP-ribose moiety of NAD+ coupled with cleavage of the nicotinamide from NAD+ and consequent production of the deacetylated protein and 2′-O-acetyl-ADP-ribose (2′-OAcADPR) [4] (Figure 1).

The seven sirtuins (SIRT1-SIRT7) present in humans have differential cellular localization. SIRT1, the human Sir2 homolog, is located mainly in the nucleus; SIRT2 is predominantly in cytoplasm but may also be present in the nucleus. SIRT6 and SIRT7 are present in the nucleus, while SIRT3, SIRT4, and SIRT5 are mitochondrial [5,6]. SIRT3 is ubiquitously expressed, especially in metabolically active tissues. SIRT3 acts as a mitochondrial deacetylase, while SIRT5 acts as both a desuccinylase and demalonylase [7]. This family of enzymes governs genome regulation, stress response, metabolic homeostasis and lifespan.

In particular SIRT1 exerts several effects in genome regulation, such as promoting the folding of chromatin into a more tightly packed form known as heterochromatin, which is associated with histone hypoacetylation and gene repression.

Moreover SIRT1 may play a relevant role in the control of metabolism and cellular differentiation, regulating negatively the activity of the histone acetyltransferase p300, a limiting transcriptional cofactor.

One of the most interesting target of SIRT1 is the tumor suppressor p53. Indeed it has been shown that SIRT1 deacetylates several lysine residues of p53, thus leading to apoptosis suppression in response to oxidative stress and DNA damage, and therefore to an increase of cell survival.

Another alternative pathway by which SIRT1 increases cell survival is through the regulation of FOXO (Forkhead box O) transcription factors. There are four FOXOs and so far SIRT1 has been shown to deacetylate three isoform: Foxo1, Foxo3a and Foxo4. SIRT1 also affects Foxo3a function in neurons and fibroblasts, reducing apoptosis in response to stress stimuli, but increasing in expression of DNA repair and cell-cycle checkpoint genes.

SIRT1 seems to play a key role also in regulating metabolism in response to dietary changes, in fact it promotes fat mobilization in white adipose tissue by binding to and repressing genes involved in adipogenesis, such as PPAR-γ (peroxisome proliferator-activated receptor γ) and aP2 (fatty acid binding protein), and also by quenching the PPAR-γ cofactors NCoR (nuclear receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptors) [8].

Considering the molecular pathways described above, in which SIRT1 is involved, compounds able to potentiate SIRT1 effects can be useful for several diseases, such as cardiovascular and neurodegenerative diseases, diabetes, obesity, inflammation and disorders related to aging. Instead, SIRT1 inhibition has been proposed for the treatment of immunodeficiency virus infections and of parasitic diseases, as well as to stimulate appetite, and/or weight gain in metabolic disorders. Both SIRT1 activation and inhibition have been proposed in cancer therapy, as well as SIRT2 inhibition [9].

*Corresponding author: Alessandra Locatelli, The Department of Pharmacy and Biotechnology FaBiT, University of Bologna, Via Belmeloro, 6, Bologna, Italy, Tel: +390512099700; E-mail: alessandra.locatelli@unibo.it

Received June 14, 2016; Accepted June 20, 2016; Published June 24, 2016

Citation: Grazia Ando A, Locatelli A, Morigi R, Rambaldi M (2016) Small-Molecules Targeting Sirtuin 1: A Patent Review (2012-2015). Med chem (Los Angeles) 6: 411-421. doi:10.4172/2161-0444.1000378

Copyright: © 2016 Grazia A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Med chem (Los Angeles) ISSN: 2161-0444 Med chem (Los Angeles), an open access journal

Volume 6(6): 411-421 (2016) - 411
Based on the large variety of SIRTs enzymatic functions, a huge amount of patents about sirtuin modulators and their possible therapeutic applications have been registered. In this review, we focused the attention on small molecules targeting SIRT1 and on their applications. Moreover, the mass spectroscopy and fluorescent based methodologies applied for the development of both SIRT1 activators and inhibitors are reported. For the patent search, the Espacenet and the Scifinder databases have been used, applying essentially the keywords “sirtuin” and the range from 2012 to 2015. Only patents published in English were considered.

Uses of Sirtuin Modulators

The SIRTs modulators include both activators and inhibitors. Until now, the activators have been described only for SIRT1. Some of these important activators (Figure 2 and Table 1) are: resveratrol (3,5,4’-trihydroxystilbene), present in several plants in particular grapes, blueberries and raspberries [10]; pinosylvin, a pre-infectious stilbenoid toxin present in the heartwood of Pinaceae [11]; the imidazo-thiazole derivate SRT1720, an experimental drug that has been studied by Sirtris Pharmaceuticals [12] and the indole-3-carbinol (I3C), a natural product of Brassica vegetables [13].

Many inhibitors have been reported for all SIRTs [14], some examples are reported in Figure 3 and Table 1.

Many SIRT1 activators, described in the reported patents, may be used for cardiovascular diseases. Among the cardiovascular diseases, there are cardiac arrhythmias, such as Brugada syndrome, still lacking an effective therapy. The Brugada syndrome, a congenital arrhythmia,
Sirtuin modulators, described in many inventions, for their anticoagulant and antithrombotic action may be used to treat blood coagulation disorders, such as myocardial infarction, stroke, or is associated with decreased expression or activity of sodium channels (Nav.5). Since SIRT1 deacetylates Nav.5 and increases sodium current, compounds that increase the activity and/or expression of SIRT1 are very effective [15]. Moreover, activators have been proposed for the treatment of neurodegenerative diseases (for examples Alzheimer’s, Parkinson’s and Huntington’s diseases, amyotrophic lateral sclerosis, ocular diseases) and traumatic or mechanical injury to the central or peripheral nervous system [16-19].

Sirtuin modulators, described in many inventions, for their anticoagulant and antithrombotic action may be used to treat blood coagulation disorders, such as myocardial infarction, stroke, or neurodegenerative diseases (for examples Alzheimer’s, Parkinson’s and Huntington’s diseases, amyotrophic lateral sclerosis, ocular diseases) and traumatic or mechanical injury to the central or peripheral nervous system [16-19].

![SIRT1 Activators and Inhibitors](image_url)

**Table 1**: Potential applications of compounds targeting SIRT1.

**Figure 3**: Examples of SIRT1 and/or SIRT2 inhibitors.
pulmonary embolism. As the sirtuins can play a key role in obesity, small molecules that modulate their activity may be used in metabolic disorders. It is known for over 80 years, that caloric restriction improves the health and extends the lifespan of mammals. However, the dietary restriction did not extend lifespan when sirtuins were deleted. This has led to suppose that the extension of life may be due to induction of SIRT1 expression, thus prompting the investigators to search activator molecules. In metabolic pathways, SIRT1 controls adipocyte cytokines expression, fat cells maturation, insulin secretion, plasma glucose levels, cholesterol and lipid homeostasis, and mitochondrial energy capacity. SIRT1 regulates the lifespan through several mechanisms. One of the most important is the interaction with coactivators, such as PGC-1 family, that have a key role in the homeostasis of glucose, lipids, and energy and are involved in disorders such as obesity, diabetes, neurodegeneration, and cardiomyopathy. SIRT1 deacetylates PGC-1, increasing its activity, and thus acting as a PGC-1 modulator [20-23]. Moreover SIRT1 is highly expressed in the hypothalamus, where regulates energy homeostasis and induces beneficial effects in the caloric restriction [24,25].

Sirtuin activators could find applications in inflammatory, allergic and respiratory disorders. Moreover, they may be useful for improving physical performances in sports activities, enhancing energy and blood oxygen levels. They reduce muscle fatigue and stress, improving muscle ATP levels and reducing lactic acid in blood, thus improving cardiovascular function. They are also effective in the treatment of pathological conditions affecting the muscle, such as acute sarcopenia, muscle atrophy or cachexia [26]. Many inventions provide indications about the increase of mitochondrial activity with sirtuin activators.

Compounds that modulate the level and/or activity of both SIRT1 and SIRT2 are considerate useful tools against tumors such as bladder, breast, cervix, head and neck, lung, colorectal, hepatocellular, pancreatic, prostate and renal carcinoma, chronic lymphocytic and myelogenous leukemia, multiple myeloma, non-Hodgkin’s lymphoma, brain tumors, melanoma, and soft tissue sarcomas [27,28].

The activity of the modulators on viral infections is not yet fully clarified, in fact both activators and inhibitors are reported for their ability to counteract the viral infections [29,30]. In two patents [29,31], Shenk et al. reported that known activators, such as polyhydroxy stilbenes, flavonoids or polyhydroxy chalcones, inhibited viral replication. The patents reported that resveratrol inhibited the effects of metabolic disorders, such as type 2 diabetes or obesity, with a terpenoid lactone bearing a 5-alkenylxoxy-furan-2-one group, analogue of strigolactone GR24 (Figure 5 and Table 1) [42].

The substrate was a 20 amino acid peptide having an acetylated lysine, as methyl. The patent reported also the synthesis using conventional techniques, from readily available starting materials. Sirtuin modulators may be conducted in a cell free or cell based system. Peptide substrates are acetylated using radiolabeled acetate. After incubation with sirtuin and test agent, the radioactive signal of the remaining peptide substrate is quantified [34]. Another assay is based on the release of nicotinamide from the NAD+ co-substrate, selectively blocked by a resin [10,35]. In one method, deacetylase activity is measured as EC50, i.e., the concentration which induces the maximum, following the required incubation time. Another assay consists in measuring the ability of a test agent to induce the release of nicotinamide, in equimolar quantities with the deacetylated peptide (see Figure 1). An increase in 2'-OAcADPR levels indicates that the test agent stimulates deacetylation, while a decrease indicates an inhibitory effect [36].

Mass spectrometry based [37] or fluorescence based assays [36] may be also used to determine sirtuin activity. An assay based on the fluorescence resonance energy transfer (FRET) technology uses a cryptate-labeled acetyl-p53 peptide (donor) and a d2-labeled anti-acetyl-p53 antibody (acceptor). In this method, deacetylase activity causes a decrease in FRET signal [36,38]. Others assays include radioimmunoassays (RIA), scintillation proximity assays, HPLC based assays and reporter gene assays (e.g., for transcription factor targets) [39].

In the mass spectrometry assay, preferred substrates are acetylated peptides (such as peptides of p53, the Fluor de Lys-SIRT1 and peptides from human histones H3 and H4). The sirtuin may be SIRT1, Sir2, SIRT3, or N-terminus portions (amino acids 1-176 or 1-255 of SIRT1; amino acids 1-174 or 1-252 of Sir2), since it has been seen that compounds interact with the N-terminus portion. The cells are incubated with the test compound and the substrate for about 1-3 hours. Nicotinamide is added as a negative control at the beginning of the reaction, since it inhibits deacetylase activity occurring the co-substrate-binding pocket. As positive control for determining the amount of deacetylation of the substrate at a given time point within the linear range, 10 nM of sirtuin protein in 1 μL of DMSO is used. This time point is the same as that used for test compounds and, within the linear range, the endpoint represents a change in enzymatic reaction kinetics [36].

In the examined patents, the degree of SIRT1 deacetylation activated by a test agent is expressed as EC50, i.e., the concentration of compound required to increase SIRT1 activity by 50% compared to the control, or as percentage of maximum activation (i.e., the maximum activity achieved relative to control (100%) at the highest concentration of the test compound). To measure the degree of activation induced by a compound, it is used also half maximal effective activating concentration (AC1/2), i.e., the concentration which induces an enzymatic activation response halfway between the baseline and maximum, following the required incubation time.

**SIRT1 Activators**

In 2012, Vu patented quinazolinone derivatives as sirtuin modulators [40]. The compounds are represented by the general formula reported in Figure 4 and Table 1, where R1 is a heterocycle or a substituted heterocycle; X is an amide; R2 is a m-trifluoromethylphenyl or a m-trifluoromethoxyphenyl moiety and R3 is a C1-C4 alkyl group such as methyl. The patent reported also the synthesis using conventional techniques, from readily available starting materials. Sirtuin modulators were identified using the mass spectrometry based assay. The substrate was a 20 amino acid peptide having an acetylated lysine, and labelled with the fluorophore 5-carboxytetramethylrhodamine (5TMR) (excitation 540 nm/emission 580 nm) at the C-terminus. The compound 1 (Figure 4 and Table 1) was the most active of the series, with an EC50 value for SIRT1 activation ≤ 50 μM and the percent maximum fold activation (FOLD) >150%, whereas it showed an IC50 value <10 μM for SIRT2 inhibition.

In 2012, Laakso et al. made an application [41] for the treatment of metabolic disorders, such as type 2 diabetes or obesity, with a terpenoid lactone bearing a 5-alkenylxoxy-furan-2-one group, analogue of strigolactone GR24 (Figure 5 and Table 1) [42]. The patent also
presented some terpenoid lactones as novel SIRT1 activators, that may be used alone or in combination with resveratrol or pinoysylvine. On the other hand, the literature reports the use of different associations, as food supplement, to increase the action of SIRT1. An example was reported in the patent [43], which described a food supplement, consisting of resveratrol, nicotinic acid or a precursor of nicotinic acid, and D-ribose. The application of Laakso, in addition to numerous assays on GR24, shows the activity of the new derivatives on SIRT1. Since the treatment of adipocytes with GR24 increased the SIRT1 expression, a first assay was conducted processing 3T3-L1 preadipocytes with 60 μM of compounds for 24 hours and compared to control (100%) and to GR24. The change in SIRT1 protein expression was produced from compound 2 (Figure 5 and Table 1) with percentage changes of 327% and 48% compared with control (100%) and GR24, respectively. Since PGC-1 is an indicator of SIRT1 activity [44], an immunoblot test evaluating the percentage changes in PGC-1α expression in 3T3-L1 preadipocytes, was conducted. The results were in agreement with the previous assay.

In 2013, Larsen et al. patented new substituted pyridine dicarboxamides, as sirtuin modulators [45]. The SIRT1 activation by test compounds was measured as a FRET induced UV signal, in presence of the acetylated and labelled with a fluorescent probe peptide substrate, where maximal signal (100%) corresponds to no activation. The detection of the activity involves quantification of the deacetylation process using nicotinamide, as inhibition control, and the compound SRT1720 [12], as activation control. Compounds 3, 4, 5 and 6 (Figure 6 and Table 1) showed clear activation, having AC50 values in the micro molar range, whereas compound 7 (Figure 6 and Table 1) showed clear inhibition of SIRT1 deacetylating activity with an IC50 value of 0.5 μM. The patent also studied ADME profiling of SIRT1 activators in order to evaluate the pharmacokinetic properties of the most interesting compounds.
In 2013, Blum et al. reported two patents [46,47] including several aza-heterocycles, in particular imidazo-pyridazines and pyrazolo-pyrimidines, as sirtuin modulators. In another patent of 2013 [48], Casaubun et al. reported a large library of similar aza-heterocycles. SIRT1 activating compounds were identified using two assays, similar to those described previously. The TAMRA based mass spectrometry assay used a peptide having sequence: Ac-EE-K(biotin)-GQSTSSHK(Nle)-STEG-K(5TMR)-EE-NH₂ (SEQ ID NO: 1), wherein K(Ac) is an acetylated lysine residue and Nle is a norleucine. The peptide was labeled with the fluorophore 5TMR at the C-terminus. The Trp based assay utilized a peptide having an amino acid residues as follows: Ac-R-H-K-K(Ac)-W-NH₂ (SEQ ID NO: 2). The activity is expressed as EC₁₅ values that represent the concentration of test compounds that results in 150% activation of SIRT1. In the series of imidazo-pyridazines [46], the most active compounds, in TAMRA assay, were 8, 9 and 10 (Figure 7 and Table 1) with EC₁₅ values <1 μM and FOLD Act >350%. Whereas in the series of pyrazolo-pyrimidines [47], the most active compound was 11 (both enantiomers) (Figure 7 and Table 1) with EC₁₅ values <1 μM for both TAMRA and Trp assays.

The library of Casaubon et al. patent [48] included 1099 compounds, of these, 76 compounds had an EC₁₅ value <1 μM and FOLD Act >350% in both assays (TAMRA and Trp). The derivate 12 (Figure 8 and Table 1) is one of the most active of the library compounds, and its synthesis is reported as example in Scheme A.

As described in the above cited patent [48], 6-chloro-4-
methylpyridazin-3-amine (a) was allowed to react with ethyl 2-chloro-3-oxobutanoate in ethanol as solvent under reflux for 48 h, to yield ethyl 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine-3-carboxylate (b). This compound was treated with 2-(trifluoromethyl)phenylboronic acid, cesium carbonate and Pd(PPh3)4 in dioxane and water and heated to 75°C for 5 h, to give ethyl 2,8-dimethyl-6-(2-trifluoromethyl)phenylimidazo[1,2-b]pyridazine-3-carboxylate (c). After ester hydrolyses, the coupling reaction was performed by adding 3-aminopyridazine hydrochloride, N,N-diisopropylethylamine (DIEA) and N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) as coupling reagent. The resulting reaction mixture was warmed to 60°C for 3.5 h, and subsequently the obtained crude product was purified by column chromatography to afford compound 12.

In 2014, Blum et al. patented novel substituted bridged urea analogues and their preparation, as sirtuin modulators [49]. Some of the most active compounds (13, 14 and 15) are reported in Figure 9 and Table 1.

The patent studied also the identification and characterization of the key functional regions of hSIRT1, by means proton-deuteron exchange mass spectrometry (HDX-MS). Indeed the rate of H-D exchange is highly dependent on the dynamic properties of the protein, with faster exchange occurring at solvent exposed and/or flexible regions and slower exchange occurring at the more buried and/or structurally rigid regions [50].

Considering that resveratrol is a SIRT1 activator, the study of stilbene and polyphenol derivatives, as sirtuin modulators, is substantially increased. In 2014, Bitzer et al. patented an invention concerning carboxylated stilbene derivatives and their use for treatment of several diseases, in particular treatment of metabolic disorders and neurodegenerative diseases [51]. Compounds of the invention are potent agonists of sirtuins, in particular SIRT1, 2 and/or 3, with increased activity compared to resveratrol. Moreover, they significantly enhance AMPK phosphorylation and the number of mitochondria in cells. The compounds were tested in vitro and compared with resveratrol for SIRT1 activation. The most active compound of the series (compound 16, Figure 10 and Table 1) produced a fold increase in SIRT1 activity versus control of 23.9 (control=1). This compound was also selected for other experiments. In the quantification of the SIRT1 agonistic effect, dose response, EC300 value (i.e., the concentration that gave 3-times the basal response of the enzyme) was 2 µM, versus a value >30 µM for resveratrol. Moreover, the selectivity on SIRT1, SIRT2 and SIRT3 was investigated. The results demonstrate that compound 16 has an agonistic activity on all three isoforms with similar dose-response behaviours on SIRT1 and SIRT2. The dose-response effect is slightly lesser on SIRT3.
The presence of SIRTs modulating ingredients in several foods has led researchers to study new natural extracts. The patent of Pan et al. [52] involves the use of isoflavones, included in the diet, to regulate SIRTs expression and activity. The invention of Buchwald-Werner et al. [53] reported that extracts of Mangifera Indica (Mango) are SIRT1 activators.

**SIRT1 Inhibitors**

Since the catalytic site of the diverse SIRT isoforms is highly conserved, in recent years several reports on SIRT1 and SIRT2 inhibitors have been published [54-56]. Interestingly, the simultaneous inhibition of SIRT1 and SIRT2 may cause cancer cell death, since p53 sirtuin-mediated deacetylation is inhibited, whereas the independent inhibition of SIRT1 and SIRT2 would be insufficient [55].

In 2014, Blum et al. [57] reported about two hundred substituted thieno[3,2-d]pyrimidine-6-carboxamide derivatives and analogues as SIRT1, SIRT2 and SIRT3 inhibitors for treating cancer, neurodegenerative disease and inflammation. Compounds of the invention are represented by general formulas reported in Figure 11 and Table 1.

Some novel derivatives were evaluated, in a biochemical assay, for their ability to inhibit the deacetylation of a peptide substrate (Ac-RHKKAcW-NH₂) in presence of SIRT1, SIRT2 or SIRT3. Compound 17 (Figure 11 and Table 1) displayed excellent potency with an IC₅₀ of 4nM for SIRT1 and SIRT3 and of 3 nM for SIRT2. Replacement of the piperidine with a piperazine reduced only slightly the potency against SIRT2, whereas SIRT1 and SIRT3 inhibition was reduced about 7-8 fold. The effect of replacing the thiophene with a phenyl ring, both in piperidine and piperazine analogues, showed a decrease in SIRT1 and SIRT2 inhibition and an improvement in SIRT3 inhibition. Since compound 17 was lacking of drug-like properties its development failed, and to explore the possibility to improve the physiochemical features, a series of analogues were synthetized and evaluated. In a first series, the replacement of the ethylamide group with tert-butyl ester, carboxylic acid or hydrogen on the thiophene ring resulted in modest reduction of inhibition activity, indicating that the ethylamide group is not essential.

![Figure 9: Substituted bridged urea analogues.](image)

![Figure 10: Stilbene derivative.](image)
for activity. Whereas, a series of truncated derivatives indicated that the thieno[3,2-d]pyrimidine-6-carboxamide core alone was not sufficient for activity. Lastly, the thiophene was replaced with an acetamide group. To further optimize the potency a larger compound set was prepared wherein acetamide group replacement with a thioacetyl-, pivaloyl-, solfonamide or pyrrolydine group was explored. Compound 18 (Figure 11 and Table 1), bearing methylsolfonamide group, showed excellent potency with IC₅₀ values of 4nM, 1nM and 7nM versus SIRT1, SIRT2 and SIRT3, respectively.

The patent described also the synthesis of the mentioned compound.
thieno[3,2-d]pyrimidine-6-carboxamide derivatives. Here we report
the synthetic pathway of compound 17 (Scheme B) as an example.
In the first step, to a solution of 5-(methoxycarbonyl)thiophene-2-
carbonyl acid (a) in DMF were added ethylamine hydrochloride, HATU and DIEA, the resulting mixture was stirred for 7 h to obtain
methyl 5-(ethylcarbamoyl)thiophene-2-carboxylate (b). The methyl
ester was hydrolyzed by LiOH to afford 5-(ethylcarbamoyl)thiophene-
2-carboxylic acid as a white solid (compound c). In the second step, to a stirring solution of 2,6,6-tetramethylpyperidine and BuLi in
THF was added 4-chlorothieno[3,2-d]pyrimidine (d) and dry ice at
-78°C, to obtain 4-chlorothieno[3,2-d]pyrimidine-6-carboxylic acid
(e). Subsequently, the acid was converted into amide (f) by adding a
solution of ammonia in dioxane. A solution of 4-chlorothieno[3,2-d]
pyrimidine-6-carboxylic acid (e), tert-butyl(2-(piperidin-4-yl)ethyl)c
ambarate and DIEA in CH$_3$CN was heated at reflux for 1 h to obtain
tert-butyl(2-(6-carboxamido)thieno[3,2-d]pyrimidin-4-yl)piperidin-
4-yl)ethyl)c
ambarate (g). The tert-butyl group was removed by trfluoroacetic acid to give compound h. In the last step, the coupling reaction between compound c and compound h was performed by
adding DIEA and HATU in DMF, to afford compound 17.

Conclusions

Since it was clarified that SIRT1 substrates are involved in a
number of biological processes, as gene transcription, cell death and
metabolism, SIRT1 has been considered an interesting target for
treating a high number of diseases. Indeed, several patents focused on
small molecules targeting SIRT1, both as activators or as inhibitors.
Noteworthy, the patented compounds bear different chemical scaffolds,
however in the considered patents the structural requirements for the
effective modulating activity on SIRT-1 were not fully clarified. Given
the interest on SIRT1 activators such as resveratrol, several studies on
stibene and polyphenol derivatives have been reported. Moreover,
some terpenoid dilactones, analogues of strigolactone GR24, were
reported as SRT1 activators useful for the treatment of metabolic
disorders. Nevertheless, most of the patented sirtuin modulators are
aza-heterocycles, in particular imidazo-pyridazines, triazolo-
pyridazines and pyrazolo-pyrimidines. Interestingly, since both
activators and inhibitors are known to counteract viral replication, it’s
presumably that further studies in this area will lead to the development
of new effective molecules. Regarding the SIRTs inhibition, it has been
reported that thieno[3,2-d]pyrimidine-6-carboxamide derivatives,
dual SIRT1 and SIRT2 inhibitors, showed antiproiferative activity.
However, further investigations are needed for their development as
anticancer agents. To conclude, the great number of patents on SIRT1
modulators indicates the relevance of this target for new therapeutic
strategies useful for the treatment of several kinds of diseases. Therefore,
as a perspective, SIRT1 modulators may reach a real application in
therapy.

References

1. Sauve AA, Wolberger C, Schramm VL, Boeke JD (2006) The biochemistry of
sirtuins. Annu Rev Biochem 75: 435-465.
2. Blander G, Guarente L (2004) The Sir2 family of protein deacetylases. Annu
Rev Biochem 73: 417-435.
3. Nguyen GT, Gertz M, Steegborn C (2013) Crystal structures of Sirt3 complexes
with 4'-bromo-resveratrol reveal binding sites and inhibition mechanism. Chem
Biol 20: 1375-1385.
4. Zheng W (2013) Mechanism-based modulator discovery for sirtuin-catalyzed
deacetylation reaction. Mini Rev Med Chem 13: 132-154.
5. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I (2005) Evolutionarily
conserved and nonconserved cellular localizations and functions of human
SIRT proteins. Mol Biol Cell 16: 4623-4635.
6. Onyango P, Cellic I, McCaffery JM, Boeke JD, Feinberg AP (2002) SIRT3,
a human SIR2 homologue, is an NAD-dependent deacetylase localized to
mitochrondria. Proc Natl Acad Sci USA 99: 13653-13658.
7. Newman JC, He W, Verdin E (2012) Mitochondrial protein acylation and
intermediary metabolism: regulation by sirtuins and implications for metabolic
disease. J Biol Chem 287: 42436-42443.
8. Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological
function. Biochem J 404: 1-13.
9. Alcain FJ, Villalba JM (2009) Sirtuin inhibitors. Expert Opin Ther Patents 19:
283-294.
10. Kaeberlein M, McDonagh T, Hellweg B, Hixon J, Westman EA, et al. (2005)
Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038-
17045.
11. Laakso M, Yaluri N (2014) Composition and method for
metabolism and treating metabolic and other disorders. US20140142170.
12. Pillarisseti S (2008) A review of Sirt1 and Sirt1 modulators in cardiovascular and
metabolic diseases. Recent Pat Cardiovasc Drug Discov 3: 156-164.
13. Choi Y, Um SJ, Park T (2013) Indole-3-carbonil directly targets SIRT1 to inhibit
adipocyte differentiation. Int J Obes (Lond) 37: 881-884.
14. Blum CA, Ellis JL, Loh C, Ng PY, Perri RB, et al. (2011) SIRT1 modulation
as a novel approach to the treatment of diseases of aging. J Med Chem 54:
417-432.
15. London B, Irani KJ (2013) Regulation of cardiac sodium channels by sirt1 and
sirt1 activators. WO2013166502.
16. Scuderi C, Slecca C, Bronziouli MR, Rolli D, Valente S, et al. (2014) Sirtuin
modulators control reactive gliosis in an in vitro model of Alzheimer’s disease.
Front Pharmacol 5: 89.
17. Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, et al. (2009) The
SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and
against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J
Neurochem 110: 1445-1456.
18. Calliari A, Bobba N, Escande C, Chini EN (2014) Resveratrol delays
Wallerian degeneration in a NAD(+)/DABC1 dependent manner. Exp
Neurool 251: 91-100.
19. Hershkovits AZ, Guarente L (2013) Sirtuin deacytelyases in neurodegenerative
diseases of aging. Cell Res 23: 746-758.
20. Cantó C, Auwerx J (2009) PGC-1alpha, SIRT1 and AMPK, an energy sensing
network that controls energy expenditure. Curr Opin Lipidol 20: 98-105.
21. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, et al. (2005) Nutrient
control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.
Nature 434: 111-118.
22. Leibiger IB, Berggren PO (2008) Sirt1: a metabolic master switch that
modulates lifespan. Nat Med 12: 34-36.
23. Lin J, Handschin C, Spiegelman BM (2005) Metabolic control through the PGC-
1 family of transcription coactivators. Cell Metab 1: 361-370.
24. Wang Y (2014) Molecular Links between Caloric Restriction and Sirt2/SIRT1
Activation. Diabetes Metab J 38: 321-329.
25. Villalba JM, Alcain FJ (2012) Sirtuin activators and inhibitors. Biofactors 38:
349-359.
26. Baur JA (2010) Biochemical effects of SIRT1 activators. Biochim Biophys Acta
1804: 1626-1634.
27. Saunders LR, Verdin E (2007) Sirtuins: critical regulators at the crossroads
between cancer and aging. Oncogene 26: 5499-5504.
28. Shih J, Dommez G (2013) Mitochondrial sirtuins as therapeutic targets for age-
related disorders. Genes Cancer 4: 91-96.
29. Koyuncu E, Budayeva HG, Miteva YV, Ricci DP, Silhavy TJ, et al. (2014)
Sirtuins are evolutionarily conserved viral restriction factors. MBio 5.
30. Li WY, Ren JH, Tao NN, Ran LK, Chen X, et al. (2016) The SIRT1 inhibitor,
icotinamide, inhibits hepatitis B virus replication in vitro and in vivo. Arch Virol
161: 621-630.
31. Shenk T, Koyuncu E, Kim H, Crietea I, MacMillan D (2015) Methods for
modulating sirtuin enzymes. US20150335657.
32. Höppner S, Schlänzer W, Thevis M (2013) Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes. Rapid Mass Commun Mass Spectrom 37: 25-30.

33. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, et al. (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383-2396.

34. Inoue A, Fujimoto D (1970) Histone deacetylase from calf thymus. Biochim Biophys Acta 220: 307-316.

35. Nayagam VM, Wang X, Tan YC, Poulsen A, Goh KC, et al. (2006) SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 11: 959-967.

36. Rye PT, Frick LE, Ozbal CC, Lamarr WA (2011) Advances in label-free screening approaches for studying sirtuin-mediated deacetylation. J Biomol Screen 16: 1217-1226.

37. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.

38. Marcotte PA, Richardson PR, Guo J, Barrett LW, Xu N, et al. (2004) Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal Biochem 332: 90-99.

39. Boss O, Worcester S, Iffland A, Smith J, Mine J, et al. (2012) Biomarkers of sirtuin activity and methods of use thereof. US20100215632.

40. Chi BV (2012) Quinazolinone and related analogs as sirtuin modulators. US20120165330.

41. Laakso M, Yaluri N (2012) Composition and method for influencing energy metabolism and treating metabolic and other disorders. WO2012056111.

42. Besserer A, Bécard G, Jauneau A, Roux C, Séjalon-Delmas N (2008) GR24, a synthetic analog of strigolactones, stimulates the mitosis and growth of the arbuscular mycorrhizal fungus Gigaspora rosea by boosting its energy metabolism. Plant Physiol 148: 402-413.

43. Pall ML (2014) Nutritional supplements and associated treatment methods. US20140031299.

44. Lagouge M, Angmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.

45. Larsen BD, Andersen S, Larsen MS (2013) Novel heterocyclic compounds useful in sirtuin binding and modulation. WO2013090389.

46. Blum CA, Springer SK, Vu CB (2013) Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators. WO2013059589.

47. Blum CA, Disch JS, Springer SK (2013) Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators. WO2013059594.

48. Casaubon RL, Narayan R, Oalmann C, Vu CB (2013) Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators. WO2013059587.

49. Blum CA, Oalmann C, Szczepaniekiewicz BG, Caldwell RD, Casaubon R, et al. (2014) Substituted bridged urea analogs as sirtuin modulators. WO2014186313.

50. Hamuro Y, Coales SJ, Southern MR, Nemeth-Cawley JF, Stranz DD, et al. (2003) Rapid analysis of protein structure and dynamics by hydrogen/deuterium exchange mass spectrometry. J Biomol Tech 14: 171-182.

51. Bitzer J, Kuper T, Wabnitz P (2014) Carboxylated stilbenes for activating AMPK and sirtuins. EP2801357.

52. Pan Y, Middleton RP (2012) Methods for regulating sirtuin gene expression. WO2012141876.

53. Buchwald-Wemer SB, Büter Berger K (2015) Mangifera indica as a sirtuin 1 activating agent. WO2015188836.

54. Banks AS, Kon N, Knight C, Matsuzomo M, Gutiérrez-Juárez R, et al. (2008) Sirt1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8: 333-341.

55. Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, et al. (2010) SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 9: 844-855.

56. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R (2012) Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 11: 443-461.

57. Disch JS, Evidor G, Chiu CH, Blum CA, Dai H, et al. (2013) Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT, SIRT2, and SIRT3. J Med Chem 56: 3666-3679.